Germany's Rhön-Klinikum H1 profit rises on increased number of patients

RHOEN-KLINIKUM Aktiengesellschaft

06/08/2026 08:09

Overview
Germany healthcare provider's H1 revenue rose slightly to EUR 863.6 mln
Net income for H1 increased to EUR 22.5 mln
Company treated 9% more patients, but warns of regulatory and economic uncertainty ahead

Outlook
Rhön-Klinikum expects 2026 revenue of EUR 1.7 bln, plus or minus 5%
Company forecasts 2026 EBITDA between EUR 110 mln and EUR 125 mln
Company says outlook is subject to uncertainty from new healthcare reforms and global crises

Result Drivers
PATIENT GROWTH - Co said number of patients treated rose 9% in H1, supporting revenue increase
REGIONAL NETWORKS - Co attributed performance to expansion and improvement of regional healthcare networks
TRANSFORMATION COSTS - Immediate transformation costs established to offset higher personnel and material costs affected results

Company press release: ID:nEQ1w0K11a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
EUR 863.60 mln
 
H1 Net Income
 
EUR 22.50 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Rhoen Klinikum AG is €14.00, about 11.1% above its August 5 closing price of €12.60
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 18 three months ago

Reuters Recommended Reads
Aug 5 - Fresenius raises 2026 outlook after Q2 profit beat
Aug 4 - Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again
Aug 5 - US Physical Therapy Q2 revenue rises on higher patient volume

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)